

## CONTENTS

<b>1. Guest editor's introduction</b> <b>J. Chapman</b>	iii 1
<b>2. Cardiovascular risk factors in renal transplantation—current controversies</b> <b>R. Marcén</b>	iii 3
<b>3. Long-term cardiovascular risk in transplantation—insights from the use of everolimus in heart transplantation</b> <b>H. Eisen</b>	iii 9
<b>4. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients</b> <b>V. Andrés, C. Castro and J. M. Campistol</b>	iii 14
<b>5. Everolimus in clinical practice—renal transplantation</b> <b>J. Pascual</b>	iii 18
<b>6. Conversion to everolimus in maintenance patients—current clinical strategies</b> <b>E. Pohanka</b>	iii 24
<b>7. Management of cardiovascular risk in patients receiving calcineurin inhibitors—a case report</b> <b>D. Serón</b>	iii 30
<b>8. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease—a case report</b> <b>V. Sparacino and S. Calabrese</b>	iii 34
<b>9. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia—a case report</b> <b>J. Pascual, A. M. Fernández, R. Marcén and J. Ortuño</b>	iii 38

All reasonable precautions have been taken by the authors, editors, and publishers to verify drug names and doses, the results of experimental work, and the clinical findings published in this Supplement. The opinions expressed are those of the authors, and not necessarily those of the editors or publishers. The ultimate responsibility for the use and dosage of drugs mentioned in this Supplement and in the interpretation of published material lies with the medical practitioners and the editors and publishers can accept no liability whatsoever in respect of any claim for damages arising therefrom. Please inform the editors of any errors.

*Please visit the Journal's World Wide Web site at [www.ndt.oxfordjournals.org](http://www.ndt.oxfordjournals.org)*